All stock lists
Unlock the score
Kura Oncology, Inc. (NASDAQ:KURA)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
9.62+0.01 (+0.10%)
Market cap
$856M
Insider Score
Health Score
Analyst consensus
Listed since
Sep 16, 2015
Website
Insider Score
/ 100
KURA Insider Score
Kura Oncology, Inc. has a live Insider Score.
Scored on 2 qualifying trades from 1 insider in the last 90 days.
Financial Health Score
Weak
From KURA’s reported statements · Q2 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $77.2M
- Net income
- -$296.8M
- Net margin
- -384.3%
Leverage15 / 20
Little or no net debt.
- Total debt
- $24.5M
- Cash
- $70.2M
- Debt / equity
- 0.50
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $559.4M
- Current liabilities
- $118.2M
- Current ratio
- 4.73
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$111.8M
- Free cash flow
- -$117.4M
- FCF margin
- -152.1%
Dilution & runway2 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 88.9M
- Share growth (1y)
- 1.4%
- Cash runway
- 8 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
KURA Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 20.87 M | 18.27 M | 17.34 M | 20.75 M | 15.29 M | 14.11 M |
| Revenue Growth (YoY) | 36.54 % | 29.47 % | -67.83 % | — | — | — |
| Cost of Revenue | 243.00 K | 617.00 K | 0.00 | 3.21 M | 0.00 | 0.00 |
| Gross Profit | 20.63 M | 17.65 M | 17.34 M | 17.54 M | 15.29 M | 14.11 M |
| SG&A Expense | 31.75 M | 31.20 M | 39.14 M | 32.84 M | 25.17 M | 22.84 M |
| R&D Expense | 61.89 M | 65.26 M | 64.41 M | 67.91 M | 62.78 M | 55.97 M |
| Operating Expenses | 93.64 M | 96.46 M | 103.60 M | 97.53 M | 87.95 M | 78.81 M |
| Operating Income | -73.01 M | -78.81 M | -86.27 M | -80.00 M | -72.67 M | -64.70 M |
| Pretax Income | -68.32 M | -73.33 M | -80.93 M | -74.12 M | -66.12 M | -57.20 M |
| Tax Provision | 5.00 K | 8.00 K | 71.00 K | 0.00 | 0.00 | 226.00 K |
| Net Income | -68.33 M | -73.33 M | -81.00 M | -74.12 M | -66.12 M | -57.43 M |
| EPS (Basic) | -0.77 | -0.83 | -0.92 | -0.85 | -0.75 | -0.66 |
| EPS (Diluted) | -0.77 | -0.83 | -0.92 | -0.85 | -0.75 | -0.66 |
| Shares Outstanding | 88.86 M | 88.61 M | 88.05 M | 87.64 M | 87.59 M | 87.42 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.